Literature DB >> 22289924

Clinical significance of CADM1/TSLC1/IgSF4 expression in adult T-cell leukemia/lymphoma.

S Nakahata1, Y Saito, K Marutsuka, T Hidaka, K Maeda, K Hatakeyama, T Shiraga, A Goto, N Takamatsu, Y Asada, A Utsunomiya, A Okayama, Y Kubuki, K Shimoda, Y Ukai, G Kurosawa, K Morishita.   

Abstract

Cell adhesion molecule 1 (CADM1/TSLC1) was recently identified as a novel cell surface marker for adult T-cell leukemia/lymphoma (ATLL). In this study, we developed various antibodies as diagnostic tools to identify CADM1-positive ATLL leukemia cells. In flow cytometric analysis, the percentages of CD4(+)CADM1(+) double-positive cells correlated well with both the percentages of CD4(+)CD25(+) cells and with abnormal lymphocytes in the peripheral blood of patients with various types of ATLL. Moreover, the degree of CD4(+)CADM1(+) cells over 1% significantly correlated with the copy number of the human T-lymphotropic virus type 1 (HTLV-1) provirus in the peripheral blood of HTLV-1 carriers and ATLL patients. We also identified a soluble form of CADM1 in the peripheral blood of ATLL patients, and the expression levels of this form were correlated with the levels of soluble interleukin 2 receptor alpha. Moreover, lymphomas derived from ATLL were strongly and specifically stained with a CADM1 antibody. Thus, detection of CD4(+)CADM1(+) cells in the peripheral blood, measurement of serum levels of soluble CADM1 and immunohistochemical detection of CADM1 in lymphomas would be a useful set of markers for disease progression in ATLL and may aid in both the early diagnosis and measurement of treatment efficacy for ATLL.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22289924     DOI: 10.1038/leu.2011.379

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  28 in total

1.  Activation of PERK-ATF4-CHOP pathway as a novel therapeutic approach for efficient elimination of HTLV-1-infected cells.

Authors:  Emi Ikebe; Sahoko Matsuoka; Kenta Tezuka; Madoka Kuramitsu; Kazu Okuma; Makoto Nakashima; Seiichiro Kobayashi; Junya Makiyama; Makoto Yamagishi; Seiichi Oyadomari; Kaoru Uchimaru; Isao Hamaguchi
Journal:  Blood Adv       Date:  2020-05-12

2.  Clinicopathological analysis in PTCL-NOS with CADM1 expression.

Authors:  Takeharu Kato; Hiroaki Miyoshi; Seiichiro Kobayashi; Noriaki Yoshida; Yoshitaka Imaizumi; Masao Seto; Kaoru Uchimaru; Yasushi Miyazaki; Koichi Ohshima
Journal:  Virchows Arch       Date:  2017-09-22       Impact factor: 4.064

3.  SynCAM, a novel putative tumor suppressor, suppresses growth and invasiveness of glioblastoma.

Authors:  Xiaoju Zhang; Wei Li; Yi Kang; Jianguo Zhang; Huijuan Yuan
Journal:  Mol Biol Rep       Date:  2013-08-02       Impact factor: 2.316

4.  Tumor Necrosis Factor α Regulates Endothelial Progenitor Cell Migration via CADM1 and NF-kB.

Authors:  Anthony R Prisco; Brian R Hoffmann; Catherine C Kaczorowski; Chris McDermott-Roe; Timothy J Stodola; Eric C Exner; Andrew S Greene
Journal:  Stem Cells       Date:  2016-03-04       Impact factor: 6.277

5.  Systematic clustering algorithm for chromatin accessibility data and its application to hematopoietic cells.

Authors:  Azusa Tanaka; Yasuhiro Ishitsuka; Hiroki Ohta; Akihiro Fujimoto; Jun-Ichirou Yasunaga; Masao Matsuoka
Journal:  PLoS Comput Biol       Date:  2020-11-30       Impact factor: 4.475

6.  Acute type adult T-cell leukemia cells proliferate in the lymph nodes rather than in peripheral blood.

Authors:  Mariko Mizuguchi; Mitsuyoshi Takatori; Shugo Sakihama; Manami Yoshita-Takahashi; Naoki Imaizumi; Yoshiaki Takahashi; Hiroo Hasegawa; Kennosuke Karube; Takuya Fukushima; Masataka Nakamura; Yuetsu Tanaka
Journal:  Cancer Gene Ther       Date:  2022-04-22       Impact factor: 5.987

7.  CADM1/TSLC1 Identifies HTLV-1-Infected Cells and Determines Their Susceptibility to CTL-Mediated Lysis.

Authors:  Kiruthika Manivannan; Aileen G Rowan; Yuetsu Tanaka; Graham P Taylor; Charles R M Bangham
Journal:  PLoS Pathog       Date:  2016-04-22       Impact factor: 6.823

8.  Advanced human T-cell leukemia virus type 1 carriers and early-stage indolent adult T-cell leukemia-lymphoma are indistinguishable based on CADM1 positivity in flow cytometry.

Authors:  Seiichiro Kobayashi; Eri Watanabe; Tomohiro Ishigaki; Nobuhiro Ohno; Koichiro Yuji; Kazumi Nakano; Tadanori Yamochi; Nobukazu Watanabe; Arinobu Tojo; Toshiki Watanabe; Kaoru Uchimaru
Journal:  Cancer Sci       Date:  2015-03-20       Impact factor: 6.716

9.  Loss of NDRG2 expression activates PI3K-AKT signalling via PTEN phosphorylation in ATLL and other cancers.

Authors:  Shingo Nakahata; Tomonaga Ichikawa; Phudit Maneesaay; Yusuke Saito; Kentaro Nagai; Tomohiro Tamura; Nawin Manachai; Norio Yamakawa; Makoto Hamasaki; Issay Kitabayashi; Yasuhito Arai; Yae Kanai; Tomohiko Taki; Takaya Abe; Hiroshi Kiyonari; Kazuya Shimoda; Koichi Ohshima; Akira Horii; Hiroshi Shima; Masafumi Taniwaki; Ryoji Yamaguchi; Kazuhiro Morishita
Journal:  Nat Commun       Date:  2014-02-26       Impact factor: 14.919

10.  CADM1 is expressed as multiple alternatively spliced functional and dysfunctional isoforms in human mast cells.

Authors:  Elena P Moiseeva; Mark L Leyland; Peter Bradding
Journal:  Mol Immunol       Date:  2012-10-11       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.